- Page 1 and 2:
An Introduction to Medicinal Chemis
- Page 3 and 4:
Preface This text is aimed at under
- Page 5 and 6:
Contents Classification of drugs xi
- Page 7 and 8:
Contents
- Page 9 and 10:
Contents xi 11.16.2 Structure
- Page 11 and 12:
Classification of drugs
- Page 13 and 14:
1 • Drugs and the medicinal chemi
- Page 15 and 16:
Whilst penicillin Drugs and the med
- Page 17:
Drugs
- Page 22 and 23:
10 The why and the wherefore Cytopl
- Page 25:
Where do drugs work? 13 Amphoterici
- Page 28:
16 Protein structure [ H O
- Page 31 and 32:
The tertiary structure of proteins
- Page 33 and 34: The tertiary structure of proteins
- Page 36 and 37: 24 Protein structure H-Bond Peptide
- Page 38: 26 Protein structure again that ter
- Page 43 and 44: Substrate binding
- Page 45 and 46: Substrate binding at an active site
- Page 47: Substrate binding
- Page 53 and 54: R The catalytic role of enzymes Thy
- Page 55 and 56: I NH 2 CHO (OH Condensation R< The
- Page 59 and 60: Nerve Neurotransmitters
- Page 61 and 62: Receptors
- Page 64 and 65: 52 Drug action at receptors Induced
- Page 66 and 67: 54 Drug action at receptors MESSENG
- Page 68: 56 Drug action at receptors RECEPTO
- Page 72 and 73: 60 Drug action at receptors left-ha
- Page 74 and 75: 62 Drug action
- Page 76 and 77: 64 Drug action
- Page 78 and 79: 66 Drug action at receptors D Neuro
- Page 81 and 82: Structure of DNA 69 NH 2 NHo NHo Ad
- Page 83: Structure
- Page 87: Drugs acting on DNA 75 CH3—N: MEC
- Page 90 and 91: 78 Nucleic acids end AMINO «A/* Ba
- Page 93: Summary 81
- Page 96 and 97: 84 Drug development
- Page 98 and 99: 86 Drug development | | Potential I
- Page 100 and 101: 88 Drug development bonding or not,
- Page 102 and 103: 90 Drug development 7.5.1 Variation
- Page 104 and 105: 92 Drug development covered
- Page 106 and 107: 94 Drug development avoiding patent
- Page 108 and 109: 96 Drug development ,OH OH GLIPINE
- Page 111: Receptor theories
- Page 115 and 116: Lead compounds
- Page 117 and 118: A case study—oxamniquine
- Page 119 and 120: A case study—oxamniquine
- Page 121 and 122: A case study—oxamniquine 109 CH 3
- Page 124 and 125: 112 Pharmacodynamics stream. Thirdl
- Page 127 and 128: Drug dose levels 115 can easily neg
- Page 129 and 130: Drug design for pharmacokinetic pro
- Page 131 and 132: Drug design
- Page 133 and 134: Drug design for pharmacokinetic pro
- Page 135 and 136:
Drug design for pharmacokinetic pro
- Page 137 and 138:
Drug design for pharmacokinetic pro
- Page 139:
grown Neurotransmitters as drugs? 1
- Page 142 and 143:
130 Quantitative structure-activity
- Page 144 and 145:
132 Quantitative structure-activity
- Page 146 and 147:
134 Quantitative structure-activity
- Page 148 and 149:
136 Quantitative structure-activity
- Page 150 and 151:
138 Quantitative structure-activity
- Page 152 and 153:
140 Quantitative structure-activity
- Page 154 and 155:
142 Quantitative structure-activity
- Page 156 and 157:
144 Quantitative structure-activity
- Page 158 and 159:
146 Quantitative structure-activity
- Page 160 and 161:
148 Quantitative structure-activity
- Page 162 and 163:
150 Quantitative structure-activity
- Page 164:
152 Quantitative structure-activity
- Page 170 and 171:
158 Antibacterial agents
- Page 173 and 174:
others. Antibacterial agents which
- Page 175 and 176:
Antibacterial agents which act agai
- Page 177 and 178:
Antibacterial agents which
- Page 179 and 180:
Antibacterial agents which inhibit
- Page 181 and 182:
Antibacterial agents which inhibit
- Page 183:
is tolerated Antibacterial agents w
- Page 186 and 187:
174 Antibacterial agents The proble
- Page 188 and 189:
176 Antibacterial agents Permeabili
- Page 190 and 191:
178 Antibacterial agents H0 2C—C
- Page 192 and 193:
180 R
- Page 195 and 196:
Antibacterial agents which inhibit
- Page 197 and 198:
Antibacterial agents which inhibit
- Page 199 and 200:
Antibacterial agents which inhibit
- Page 201 and 202:
Antibacterial agents which inhibit
- Page 203 and 204:
Antibacterial agents which inhibit
- Page 205 and 206:
Antibacterial agents which inhibit
- Page 207 and 208:
Antibacterial agents which
- Page 209 and 210:
Antibacterial agents which
- Page 211 and 212:
Antibacterial agents which impair p
- Page 213 and 214:
Agents which
- Page 215 and 216:
Drug resistance 203 10.9 Drug resis
- Page 217 and 218:
11- The peripheral nervous system
- Page 219 and 220:
Motor nerves
- Page 221 and 222:
Actions
- Page 223 and 224:
The cholinergic system 211 I j V Ac
- Page 225:
Agonists
- Page 229:
Agonists at the cholinergic recepto
- Page 232 and 233:
220 The peripheral nervous system
- Page 235 and 236:
Antagonists
- Page 237:
Structural analogues based Antagoni
- Page 240 and 241:
228 The peripheral nervous system I
- Page 242 and 243:
230 The peripheral nervous system p
- Page 244 and 245:
232 The peripheral nervous system ;
- Page 247:
Anticholinesterases
- Page 250 and 251:
238 The peripheral nervous system r
- Page 253 and 254:
Anticholinesterase drugs
- Page 255 and 256:
Anticholinesterase drugs
- Page 257:
Pralidoxime—an organophosphate an
- Page 260 and 261:
248 The opium analgesics Chinese de
- Page 263:
Morphine
- Page 267:
Development of morphine analogues 2
- Page 270 and 271:
258 The opium analgesics R= ——C
- Page 272 and 273:
260 The opium analgesics (A) BINDIN
- Page 274 and 275:
262 The opium analgesics morphine.
- Page 276 and 277:
264 The opium analgesics o N——C
- Page 278 and 279:
266 The opium analgesics morphine
- Page 281 and 282:
Receptor theory
- Page 283 and 284:
Receptor theory
- Page 285:
Agonists
- Page 289 and 290:
e Receptor mechanisms 277
- Page 291 and 292:
membrane to a second membrane-bound
- Page 296 and 297:
284 Cimetidine—a rational approac
- Page 299:
Searching
- Page 302 and 303:
290 Cimetidine—a rational approac
- Page 305:
From partial agonist
- Page 309:
Development of metiamide 297 the sa
- Page 313:
Cimetidine
- Page 316 and 317:
304 Cimetidine — a rational appro
- Page 318 and 319:
306 Cimetidine—a rational approac
- Page 320 and 321:
308 Cimetidine—a rational approac
- Page 324 and 325:
312 Cimetidine—a rational approac
- Page 326 and 327:
Appendix
- Page 329:
a The action of nerves 317
- Page 332 and 333:
Appendix
- Page 334 and 335:
322 Secondary messengers number
- Page 337 and 338:
Secondary messengers
- Page 339 and 340:
Haemophilus influenzae Bacteroides
- Page 341 and 342:
Glossary
- Page 343:
Index acetylcholine 47-8, 207, 209-
- Page 346 and 347:
334 Index intestinal infections
- Page 348:
336 Index structure-activity analys